Salvage prostate brachytherapy after definitive external radiation: tried and now tested

Young Kwok, Mannat Narang, Jason K. Molitoris

Abstract

Definitive external beam radiation therapy (EBRT) has long been one of the standard treatment modalities for prostate cancer. However, 15–75% of patients will experience a disease recurrence depending on such factors as the risk group, use and length of androgen deprivation therapy (ADT) and radiation dose (1). Approximately 25% of patients with biochemical recurrence will have local clinical disease progression within 5 years (2).